Build models from the highest quality data.
Data and KOL network
Challenges
Our federated learning software and research network provide us with unrivaled access to high-quality, high-value data.
GDPR and GCP compliant data
Our federated learning technology allows privacy-preserving remote access and computing of pseudonymized data.
Privileged and curated high-quality data access
Our collaborative relationships with medical experts and data providers ensure access to continuously updated top-quality data.
Accelerated data access
Our world-class Data Network provides accelerated data access compared to standard practices.
Rich longitudinal follow up
Our longitudinal datasets follow outcome and treatment response data from patient diagnosis to death/long-term cure.
High dimensional & multimodal datasets
Our multimodal datasets include tabular, clinical, histology, genomic and imaging data.
GDPR and GCP compliant data
Our federated learning technology allows privacy-preserving remote access and computing of pseudonymized data.
Privileged and curated high-quality data access
Our collaborative relationships with medical experts and data providers ensure access to continuously updated top-quality data.
Accelerated data access
Our world-class Data Network provides accelerated data access compared to standard practices.
Rich longitudinal follow up
Our longitudinal datasets follow outcome and treatment response data from patient diagnosis to death/long-term cure.
High dimensional & multimodal datasets
Our multimodal datasets include tabular, clinical, histology, genomic and imaging data.
Our growing patient data and KOL network
Data access
Expand your access to high quality multimodal data and accelerate research
Join our Federated Data NetworkTo empower your teams to:
Identify patient subgroups
Develop diagnostic tools to efficiently identify specific patient subgroups.
Discover biomarkers
Identify precise disease biomarkers of survival, recurrence and response to treatment from multimodal datasets.
Accelerate clinical trials
Develop standard analysis and novel AI-based analysis methods to accelerate and optimize your clinical trials.
Collaborate at scale
Foster unprecedented data collaborations that are secure and regulatory compliant via our federated learning software, Substra.
Identify patient subgroups
Develop diagnostic tools to efficiently identify specific patient subgroups.
Discover biomarkers
Identify precise disease biomarkers of survival, recurrence and response to treatment from multimodal datasets.
Accelerate clinical trials
Develop standard analysis and novel AI-based analysis methods to accelerate and optimize your clinical trials.
Collaborate at scale
Foster unprecedented data collaborations that are secure and regulatory compliant via our federated learning software, Substra.
Identify patient subgroups
Develop diagnostic tools to efficiently identify specific patient subgroups.
Discover biomarkers
Identify precise disease biomarkers of survival, recurrence and response to treatment from multimodal datasets.
Accelerate clinical trials
Develop standard analysis and novel AI-based analysis methods to accelerate and optimize your clinical trials.
Collaborate at scale
Foster unprecedented data collaborations that are secure and regulatory compliant via our federated learning software, Substra.
Identify patient subgroups
Develop diagnostic tools to efficiently identify specific patient subgroups.
Discover biomarkers
Identify precise disease biomarkers of survival, recurrence and response to treatment from multimodal datasets.
Accelerate clinical trials
Develop standard analysis and novel AI-based analysis methods to accelerate and optimize your clinical trials.
Collaborate at scale
Foster unprecedented data collaborations that are secure and regulatory compliant via our federated learning software, Substra.
Collaboration in healthcare
Owkin is proof that collaboration in healthcare could make precision medicine a reality.
Through data access and KOL insight, we’ve created breakthrough models
Professor Fabrice André, MD, PhD
Director of Research Gustave Roussy
"Owkin is leading the use of AI for prediction and drug discovery in cancer. It has developed methods to detect predictive signals that the human brain can’t. We developed a pathology tool to predict relapse in early stage breat cancer patients in one year, while we struggled for many years to do it with other teams."
Professor Francoise Galateau Sallé, MD, PhD
Head of MESOPATH in the Department of Biopathology Cancer Centre Léon Bérard
“We had a wonderful experience with Owkin…they created an algorithm and the results exceeded our expectations. They were able to identify details from the histology slides that we knew about but had never previously recognized as significant prognostic indicators or biomarkers of treatment decisions.”
Professor William R. Jarnigan , MD
Chief of Hepatopancreatobiliary Service at Memorial Sloan Kettering Cancer Center
“I am excited to be part of this cutting-edge research collaboration that will have a positive impact on how clinicians evaluate and treat patients with intrahepatic cholangiocarcinoma, and potentially other cancers, as well.”
Professor Fabrice André, MD, PhD
Director of Research Gustave Roussy
"Owkin is leading the use of AI for prediction and drug discovery in cancer. It has developed methods to detect predictive signals that the human brain can’t. We developed a pathology tool to predict relapse in early stage breat cancer patients in one year, while we struggled for many years to do it with other teams."
Professor Francoise Galateau Sallé, MD, PhD
Head of MESOPATH in the Department of Biopathology Cancer Centre Léon Bérard
“We had a wonderful experience with Owkin…they created an algorithm and the results exceeded our expectations. They were able to identify details from the histology slides that we knew about but had never previously recognized as significant prognostic indicators or biomarkers of treatment decisions.”
Professor William R. Jarnigan , MD
Chief of Hepatopancreatobiliary Service at Memorial Sloan Kettering Cancer Center
“I am excited to be part of this cutting-edge research collaboration that will have a positive impact on how clinicians evaluate and treat patients with intrahepatic cholangiocarcinoma, and potentially other cancers, as well.”
Take a closer look
